Brief: Spago Nanomedical Receives Approval To Start Clinical Phase I/Iia

Spago Nanomedical AB (publ)

19/10/2023 06:09

Oct 19 (Reuters) - Spago Nanomedical AB (publ)
 SPAGO.ST :
    * SPAGO NANOMEDICAL RECEIVES APPROVAL TO INITIATE THE
CLINICAL
PHASE I/IIA STUDY WITH TUMORAD® IN AUSTRALIA
    * FIRST PATIENT IS EXPECTED TO BE INCLUDED SHORTLY
    * APPLICATION TO START CLINICAL PHASE I/IIA STUDY,
TUMORAD-01,
WITH CANDIDATE DRUG 177LU-SN201 IN CANCER PATIENTS HAS BEEN
APPROVED

Source text for Eikon:  ID:nMFNL880D 
Further company coverage:  SPAGO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 58 769 66 00;))